1. January 2008 May 2008

2. Mission Statement The fetus care BioPad™’s mission is to become a world leader in the field of pre-natal care by making consumer-based medical devices that improve the pregnancy experience for women and their families.

3. Introducing Biopad’s Fetal Monitors The fetus care  BioPad makes home-use fetal activity detectors and data loggers  Products are passive and non- radiating  Small, convenient, elegant and hygienic  Can be used anywhere, anytime.

4.  Scientific evidence suggests fetal activity is a clear indicator of wellbeing  A common medical practice is a daily manual fetal kick count by the mother (‘count to 10’)  Kick count is directly linked to lower stillbirth rates (20%-30%)  Research also shows that kick counting improves the pregnancy experience Why Fetal Movements ? The fetus care

5. Common Poster at Doctors’ Offices

6. The fetus care  Monitoring  Reassurance  Procedure  Discerning  Bonding  Dialog  Connecting Customer Needs

7. The Products – Kicker Ticker 2 The fetus care  Medical device that requires FDA approval  Consists of device (for single pregnancy) and disposable pad (one for each test)  Provides automatic and accurate monitoring  Counts and stores fetal movements (trends)  Shows real-time results  Sounds & light indications  Data output (via USB) to be shared with doctor  Each session lasts 20 minutes and can take place anywhere

8. The fetus care Prototype Testing Completed Successfully!

9. The Products – Kicker Ticker 1 The fetus care  Non-medical, pregnancy experience focused  Intended to share movements with family members and friends  The Companion Egg™ responds to movements with tactile and light elements, creating tangible “event”  Does not require FDA approval  Fast time to market Movements Light Sounds

10. The Market is Significant The fetus care

11. Substantial Sales Potential  KT2 costs to woman - $120  KT1 costs to woman- $80  Family set - $150 (Includes sensor & 3 Companion Eggs™)  Potential of +$100 million in income in year 5 of operations

12. Company Needs  $2 - $3 million second round financing  Strategic partnerships:  Manufacturing  Distribution  Marketing The fetus care

13. Hanoch Kaftzan BioPad CEO T: 972.3.6093085 M: 972.52.6299629 F:972.3.6093089 Ayalon House, 16th floor 12 Abba Hillel St. Ramat Gan PO Box 25290, Tel Aviv 61251